As BCL-2 family members have been reported to be highly expressed in cervical cancer, BH3 mimetics may have therapeutic potential in these cancers and the high expression of Mcl-1 has been implicated as a resistance mechanism to these inhibitors [46, 47]. This evidence concerns the gene BCL2 and cervical carcinoma.